Abstract #277: The Benefits of the I-Port System Usage in an Insulin Dependent Patients

2017 ◽  
Vol 23 ◽  
pp. 72-73
Author(s):  
Amal Khan
Keyword(s):  
System Usage ◽  
Insulin Dependent ◽  
Port System

Low-voltage field-emission SEM of polymeric membranes for glucose biosensors

1990 ◽  
Vol 48 (3) ◽  
pp. 860-861
Author(s):  
Lorna K. Mayo ◽  
Kenneth C. Moore ◽  
Mark A. Arnold
Keyword(s):  
Glucose Sensor ◽  
Low Voltage ◽  
Glucose Sensors ◽  
Polymeric Membranes ◽  
Artificial Endocrine Pancreas ◽  
Self Monitoring ◽  
Conducting Materials ◽  
Insulin Dependent ◽  
Living Tissues ◽  
Voltage Scanning

An implantable artificial endocrine pancreas consisting of a glucose sensor and a closed-loop insulin delivery system could potentially replace the need for glucose self-monitoring and regulation among insulin dependent diabetics. Achieving such a break through largely depends on the development of an appropriate, biocompatible membrane for the sensor. Biocompatibility is crucial since changes in the glucose sensors membrane resulting from attack by orinter action with living tissues can interfere with sensor reliability and accuracy. If such interactions can be understood, however, compensations can be made for their effects. Current polymer technology offers several possible membranes that meet the unique chemical dynamics required of a glucose sensor. Two of the most promising polymer membranes are polytetrafluoroethylene (PTFE) and silicone (Si). Low-voltage scanning electron microscopy, which is an excellent technique for characterizing a variety of polymeric and non-conducting materials, 27 was applied to the examination of experimental sensor membranes.

Factors predicting well-being in adolescents with insulin-dependent diabetes

2002 ◽  
Author(s):  
J. M. Koot ◽  
A. Oldenhave ◽  
G. J. Bruining ◽  
H. J. Aanstoot
Keyword(s):  
Well Being ◽  
Insulin Dependent Diabetes ◽  
Insulin Dependent

Elevated Circulating P-Selectin in Insulin Dependent Diabetes Mellitus

1996 ◽  
Vol 76 (03) ◽  
pp. 328-332 ◽  
Author(s):  
Bernd Jilma ◽  
Peter Fasching ◽  
Christine Ruthner ◽  
Anna Rumplmayr ◽  
Sabine Ruzicka ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Plasma Levels ◽  
Plasma Concentrations ◽  
Insulin Dependent Diabetes Mellitus ◽  
Interquartile Range ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Intergroup Comparison ◽  
Median Plasma ◽  
Insulin Dependent

SummaryBased on findings that showed increased P-selectin expression on platelets and on choroidal microvessels of patients with insulin dependent diabetes mellitus (IDDM), we hypothesized that also plasma concentrations of circulating (c)P-selectin would be increased in these patients.The aim of this study was to compare the plasma levels of cP-selec-tin between non-smoking patients with IDDM, treated with an intensified insulin therapy, and healthy controls. The study design was prospective, cross-sectional and analyst-blinded. Subjects were matched individually for sex, age and body mass index. Plasma levels of cP-selectin and of von Willebrand antigen (vWF-Ag) were determined by enzyme linked immunoassays.Forty-two pairs were available for intergroup comparison. Median plasma concentrations of cP-selectin in patients with IDDM (285 ng/ml; interquartile range: 233-372) were on average 21% higher than those of controls (236 ng/ml; interquartile range: 175-296; p = 0.004). Also, median plasma levels of vWF-Ag were 10% higher in patients (96 U/dl; interquartile range: 82-127) than controls (87 U/dl; interquartile range: 70-104; p = 0.025). There was no correlation between plasma concentrations of cP-selectin and vWF-Ag levels in either group (p ώ0.05).In conclusion, our results of increased cP-selectin levels are in line with increased P-selectin expression on platelets and on choroidal microvessels found in patients with IDDM. In view of the currently developed small molecule inhibitors of cell adhesion molecules, these independent observations together may provide a sound rationale to select P-selectin as a target for treating or preventing IDDM-associated micro- or macrovascular complications.

Urinary Beta-Thromboglobulin Correlates with Impairment of Renal Function in Patients with Diabetic Nephropathy

1986 ◽  
Vol 56 (02) ◽  
pp. 229-231 ◽  
Author(s):  
A H Hopper ◽  
H Tindall ◽  
J A Davies
Keyword(s):  
Renal Function ◽  
Diabetic Nephropathy ◽  
Microvascular Disease ◽  
Normal Subjects ◽  
Specific Protein ◽  
Creatinine Concentration ◽  
Β2 Microglobulin ◽  
Plasma Creatinine Concentration ◽  
Insulin Dependent ◽  
Indium 111

SummaryTBeta-thromboglobulin (βTG) is a platelet-specific protein and since its concentration in plasma rises when platelets are activated, it has been used as an indicator of platelet involvement in vascular disease. Since platelets might be involved in the pathogenesis of diabetic microvascular disease we measured urinary βTG in 20 insulin-dependent diabetics with nephropathy and compared the results with those from 20 normal subjects. Measurement of βTG in urine was undertaken to avoid errors induced by blood sampling and to gain information over a prolonged period using a single assay. Measurements were made of βTG, β2-microglobulin and total protein in urine collected for 24 h and creatinine and β2 microglobulin in plasma. Survival of indium-111-labelled platelets was measured in nine patients. Urinary PTG was significantly (p <0.02) increased in the 20 patients compared with 20 normal volunteers (median value 1.3 vs 0.8 μg/24 h). There was a strong correlation between urinary βTG excretion and plasma creatinine concentration (r = 0.8, p <0.0001) and plasma β2-microglobulin concentration (r = 0.9, p <0.0001). Urinary βTG concentration did not correlate with platelet survival. The results indicate that although urinary βTG is significantly increased in patients with diabetic nephropathy its concentration in urine correlates with indicators of glomerular filtration rather than with a test of platelet activation.

Platelet Behaviour in Non-Insulin-Dependent Diabetes -Influence of Vascular Complications, Treatment and Metabolic Control

1986 ◽  
Vol 55 (03) ◽  
pp. 361-365 ◽  
Author(s):  
I Peacock ◽  
M Hawkins ◽  
S Heptinstall
Keyword(s):  
Blood Glucose ◽  
Metabolic Control ◽  
Platelet Reactivity ◽  
Platelet Rich Plasma ◽  
Vascular Complications ◽  
Adenosine Diphosphate ◽  
Glycosylated Haemoglobin ◽  
Insulin Dependent Diabetes ◽  
Lipid Levels ◽  
Insulin Dependent

SummaryPlatelet-rich plasma was prepared from 47 patients with noninsulin-dependent diabetes treated with glibenclamide and metformin, and 21 controls. The release of radio-labelled 5-hydroxy-tryptamine in response to aggregating agents (adenosine diphosphate, adrenaline and sodium arachidonate), and the effects on release of a selective thromboxane inhibitor (UK-34787) were investigated. Subsequently, 20 of the diabetic subjects were chosen at random for treatment with insulin; the remainder continued to take tablets. Platelet studies were then repeated, in all patients, after 4 and 6 months.The results showed an association between platelet behaviour and the presence of vascular complications, and were consistent with previous observations of reduced platelet reactivity in patients taking sulphonylureas. There was no correlation of platelet reactivity with blood glucose, glycosylated haemoglobin or lipid levels.

Sign in / Sign up

Export Citation Format

Share Document